APVO Executes Second Stock Consolidation This Year With 1-for-18 Reverse Stock Split Effective December 29

Biotechnology firm Aptevo Therapeutics Inc. is moving forward with another equity restructuring, announcing a reverse stock split that will reshape its capital structure heading into the new year. The consolidation, set to take effect on December 29, 2025, at 5:01 p.m. ET, marks the second such action the clinical-stage company has undertaken in 2025.

Split Mechanics and Timeline

Under the reverse stock split arrangement, every 18 shares held by shareholders will automatically convert into a single share. This consolidation will reduce the total share count from around 18 million shares to approximately 1 million shares. Trading on the Nasdaq Capital Market will resume on a split-adjusted basis when markets open on December 30, 2025. The stock’s par value will maintain its current level of $0.001 per share, unaffected by the consolidation.

Market Context and Recent Performance

APVO shares have displayed volatile price action throughout 2025, fluctuating between $0.50 and $109.80 during the year. Most recently, the stock closed Friday’s trading session at $0.60, reflecting a 34.73% decline from the previous close. This latest reverse stock split comes just months after Aptevo executed a 1-for-20 consolidation that became effective on May 27, 2025—indicating the company’s continued efforts to adjust its capital structure.

The consolidation activity underscores typical strategies employed by clinical-stage biotechnology companies to maintain listing compliance and stabilize share valuations amid development-stage operations.

Disclaimer: The information and analysis presented represent market observations and should not be construed as official statements from Nasdaq, Inc. or investment recommendations.